News | August 08, 2024
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
Expect the international business including CDMO business to pick-up in the second half of the financial year
Expect the international business including CDMO business to pick-up in the second half of the financial year
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
Launch of Indian public health standards for Ayush healthcare facilities
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Subscribe To Our Newsletter & Stay Updated
